Bluebird Bio Stock Probability Of Bankruptcy

BLUE Stock

USD 0.38 0.01 2.70%

Bluebird Bio's chance of distress is over 65% at the present time. It has high odds to experience some financial distress in the next few years. Bluebird Bio's Probability of distress is determined by interpolating and adjusting Bluebird Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the Bluebird balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Bluebird Bio Piotroski F Score and Bluebird Bio Altman Z Score analysis.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

Bluebird bio Company probability of distress Analysis

Bluebird Bio's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Bluebird Bio Probability Of Bankruptcy

Over 79%

Most of Bluebird Bio's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bluebird bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Bluebird Bio probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Bluebird Bio odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Bluebird bio financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.80)

Revenue Per Share

0.357

Quarterly Revenue Growth

1.337

Return On Assets

(0.36)

Return On Equity

(1.87)

The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.56	-0.42	-0.24	0.56	0.92	0.69	0.95	-0.07	0.45	0.52	0.94	0.7	0.31	0.84	0.55	-0.32	0.51	0.75	0.64	0.64	0.14	0.1	-0.1
Total Stockholder Equity	0.96		0.67	-0.61	-0.02	0.45	0.95	0.55	0.98	-0.29	0.24	0.3	0.99	0.59	0.09	0.83	0.41	-0.32	0.54	0.84	0.5	0.51	0.35	0.31	-0.25
Current Deferred Revenue	0.56	0.67		-0.78	0.29	0.14	0.57	0.06	0.68	-0.48	-0.05	-0.06	0.65	0.08	-0.19	0.5	-0.01	-0.46	0.41	0.52	0.07	0.09	0.51	0.47	-0.35
Net Debt	-0.42	-0.61	-0.78		-0.57	0.08	-0.47	0.2	-0.65	0.71	0.37	0.36	-0.62	0.06	0.54	-0.44	0.25	0.25	-0.41	-0.55	0.12	0.1	-0.7	-0.7	0.58
Retained Earnings	-0.24	-0.02	0.29	-0.57		-0.61	-0.03	-0.74	-0.04	-0.79	-0.92	-0.81	0.04	-0.74	-0.77	-0.13	-0.89	0.37	0.07	0.19	-0.82	-0.8	0.91	0.92	-0.67
Accounts Payable	0.56	0.45	0.14	0.08	-0.61		0.51	0.76	0.46	0.31	0.6	0.49	0.42	0.76	0.58	0.43	0.74	-0.36	0.16	0.19	0.75	0.76	-0.39	-0.43	0.2
Short Term Investments	0.92	0.95	0.57	-0.47	-0.03	0.51		0.59	0.91	-0.34	0.17	0.23	0.96	0.56	0.06	0.76	0.42	-0.28	0.41	0.76	0.47	0.48	0.38	0.33	-0.3
Total Liab	0.69	0.55	0.06	0.2	-0.74	0.76	0.59		0.56	0.43	0.76	0.79	0.52	0.91	0.62	0.49	0.91	-0.37	0.15	0.24	0.91	0.92	-0.44	-0.47	0.46
Total Current Assets	0.95	0.98	0.68	-0.65	-0.04	0.46	0.91	0.56		-0.29	0.25	0.31	0.98	0.6	0.06	0.8	0.42	-0.38	0.5	0.76	0.54	0.55	0.32	0.29	-0.22
Short Term Debt	-0.07	-0.29	-0.48	0.71	-0.79	0.31	-0.34	0.43	-0.29		0.8	0.76	-0.36	0.45	0.82	0.02	0.53	0.04	0.07	-0.35	0.5	0.47	-0.9	-0.89	0.74
Common Stock	0.45	0.24	-0.05	0.37	-0.92	0.6	0.17	0.76	0.25	0.8		0.9	0.16	0.8	0.83	0.4	0.87	-0.35	0.24	0.03	0.84	0.81	-0.79	-0.81	0.63
Property Plant Equipment	0.52	0.3	-0.06	0.36	-0.81	0.49	0.23	0.79	0.31	0.76	0.9		0.25	0.78	0.85	0.37	0.78	-0.2	0.19	0.16	0.83	0.8	-0.66	-0.69	0.63
Net Tangible Assets	0.94	0.99	0.65	-0.62	0.04	0.42	0.96	0.52	0.98	-0.36	0.16	0.25		0.55	0.04	0.78	0.37	-0.3	0.48	0.85	0.46	0.48	0.41	0.37	-0.29
Long Term Debt	0.7	0.59	0.08	0.06	-0.74	0.76	0.56	0.91	0.6	0.45	0.8	0.78	0.55		0.62	0.55	0.94	-0.37	0.24	0.38	0.97	0.97	-0.47	-0.51	0.42
Net Receivables	0.31	0.09	-0.19	0.54	-0.77	0.58	0.06	0.62	0.06	0.82	0.83	0.85	0.04	0.62		0.25	0.65	-0.06	0.19	0.07	0.66	0.62	-0.71	-0.74	0.68
Good Will	0.84	0.83	0.5	-0.44	-0.13	0.43	0.76	0.49	0.8	0.02	0.4	0.37	0.78	0.55	0.25		0.4	-0.28	0.87	0.64	0.43	0.43	0.14	0.12	-0.13
Capital Surpluse	0.55	0.41	-0.01	0.25	-0.89	0.74	0.42	0.91	0.42	0.53	0.87	0.78	0.37	0.94	0.65	0.4		-0.52	0.1	0.16	0.95	0.95	-0.64	-0.68	0.54
Deferred Long Term Liab	-0.32	-0.32	-0.46	0.25	0.37	-0.36	-0.28	-0.37	-0.38	0.04	-0.35	-0.2	-0.3	-0.37	-0.06	-0.28	-0.52		-0.14	-0.02	-0.45	-0.47	0.2	0.23	-0.13
Intangible Assets	0.51	0.54	0.41	-0.41	0.07	0.16	0.41	0.15	0.5	0.07	0.24	0.19	0.48	0.24	0.19	0.87	0.1	-0.14		0.47	0.12	0.11	0.17	0.17	-0.06
Long Term Investments	0.75	0.84	0.52	-0.55	0.19	0.19	0.76	0.24	0.76	-0.35	0.03	0.16	0.85	0.38	0.07	0.64	0.16	-0.02	0.47		0.23	0.25	0.46	0.41	-0.32
Long Term Debt Total	0.64	0.5	0.07	0.12	-0.82	0.75	0.47	0.91	0.54	0.5	0.84	0.83	0.46	0.97	0.66	0.43	0.95	-0.45	0.12	0.23		1.0	-0.56	-0.6	0.49
Short Long Term Debt	0.64	0.51	0.09	0.1	-0.8	0.76	0.48	0.92	0.55	0.47	0.81	0.8	0.48	0.97	0.62	0.43	0.95	-0.47	0.11	0.25	1.0		-0.54	-0.57	0.48
Net Invested Capital	0.14	0.35	0.51	-0.7	0.91	-0.39	0.38	-0.44	0.32	-0.9	-0.79	-0.66	0.41	-0.47	-0.71	0.14	-0.64	0.2	0.17	0.46	-0.56	-0.54		1.0	-0.71
Net Working Capital	0.1	0.31	0.47	-0.7	0.92	-0.43	0.33	-0.47	0.29	-0.89	-0.81	-0.69	0.37	-0.51	-0.74	0.12	-0.68	0.23	0.17	0.41	-0.6	-0.57	1.0		-0.71
Capital Stock	-0.1	-0.25	-0.35	0.58	-0.67	0.2	-0.3	0.46	-0.22	0.74	0.63	0.63	-0.29	0.42	0.68	-0.13	0.54	-0.13	-0.06	-0.32	0.49	0.48	-0.71	-0.71

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	(0.25)	(0.46)	(0.35)	(0.95)	(0.48)	(0.36)
Asset Turnover	0.0259	0.14	0.006167	0.006482	0.0476	0.0282
Gross Profit Margin	0.96	0.98	0.93	(9.61)	(1.8)	(0.14)
Net Debt	(136.2M)	(124.7M)	(71.6M)	168.4M	193.6M	203.3M
Total Current Liabilities	223.6M	203.6M	153.0M	128.2M	200.1M	114.3M
Non Current Liabilities Total	218.9M	222.6M	66.5M	230.3M	224.5M	161.3M
Total Assets	1.7B	1.8B	593.8M	554.9M	619.2M	1.1B
Total Current Assets	1.2B	1.2B	336.5M	199.5M	281.7M	267.6M
Total Cash From Operating Activities	(564.4M)	(470.4M)	(635.6M)	(353.0M)	(235.0M)	(246.8M)

	Return On Equity	-1.87
	Return On Asset	-0.36
	Operating Margin	(5.49) %
	Current Valuation	371.21 M
	Shares Outstanding	194.44 M
	Shares Owned By Insiders	0.63 %
	Shares Owned By Institutions	43.68 %
	Number Of Shares Shorted	43.64 M
	Price To Earning	(19.32) X
	Price To Book	0.73 X
	Price To Sales	1.34 X
	Revenue	29.5 M
	Gross Profit	(247.24 M)
	EBITDA	(302.11 M)
	Net Income	(211.91 M)
	Cash And Equivalents	132.51 M
	Cash Per Share	1.72 X
	Total Debt	424.62 M
	Debt To Equity	1.63 %
	Current Ratio	1.12 X
	Book Value Per Share	1.01 X
	Cash Flow From Operations	(235.05 M)
	Short Ratio	9.53 X
	Earnings Per Share	(1.80) X
	Price To Earnings To Growth	0.32 X
	Target Price	2.36
	Number Of Employees	375
	Beta	0.8
	Market Capitalization	73.46 M
	Total Asset	619.16 M
	Retained Earnings	(4.26 B)
	Working Capital	81.57 M
	Current Asset	523.97 M
	Current Liabilities	40.37 M
	Net Asset	619.16 M

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Bluebird Bio Stock Probability Of Bankruptcy

Bluebird bio Company probability of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Bluebird Bio Probability Of Bankruptcy

Bluebird Probability Of Bankruptcy Driver Correlations

Bluebird Probability Of Bankruptcy Peer Comparison

Bluebird Bio Main Bankruptcy Drivers

Bluebird Fundamentals

About Bluebird Bio Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY